-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Since the beginning of this year, the wave of resignations in the pharmaceutical industry has continued in the industry.
As of October 22 alone, there have been 25 pharmaceutical company executive positions that have changed, involving 23 pharmaceutical companies
.
Among them, there are 18 pharmaceutical companies with senior executives resigning
.
It is reported that these executives involve positions such as chairman, president, and general manager
.
The reasons for resignation mainly include personal reasons and job changes
.
For example, the Human Resources Department of BeiGene announced to employees that the national head of blood tumor sales, Shi Hao, will leave the company on November 15, 2021, to seek external development opportunities
.
The successor has not yet been determined.
Liu Yan, the head of marketing of BeiGene Greater China, will be in charge of the blood tumor sales team.
The handover has already begun.
From the 16th of next month, the blood team of BeiGene will report directly to Liu Flame
.
It is understood that more than one executive from BeiGene has left this year
.
On October 1st, Wu Qingyi, its senior vice president and chief commercial officer of Greater China, also left the company to seek external development opportunities
.
On the same day, Novartis Oncology AMACO Regional Marketing Director Pu Cunxia announced to employees that Novartis Oncology (China) General Manager Alexandre Gibim will be transferred to Novartis's AAA platform as the head of North America, effective from January 1, 2022
.
According to public information, Alexandre Gibim was transferred to Novartis Oncology (China) General Manager on March 1, 2019, and previously served as Novartis (Brazil) President
.
At the same time, from November 1st, IsabelAfonso will take over as the general manager of Novartis Oncology (China), report to Pu Cunxia, the regional market leader of Novartis Oncology AMACO, and join the Novartis Oncology AMACO leadership team
.
It is reported that Isabel Afonso was a 16-year veteran of Novartis and held business and functional leadership positions in Novartis Pharmaceuticals, Animal Health, Consumer Health and Sandoz
.
In addition, SINBON Pharmaceutical also announced on October 24 that it had received a written resignation report from the company’s securities affairs representative Mr.
Lin Hanlin on the 22nd.
.
Due to job adjustments, Mr.
Lin Hanlin applied to resign from the post of securities affairs representative
.
In fact, the frequent resignations or job transfers of senior executives in the pharmaceutical industry have long been the norm in the industry
.
The analysis believes that the industry-driven senior management changes in pharmaceutical companies are mainly due to two reasons.
One is that with the environmental changes in the pharmaceutical industry, innovation has become the development trend of the industry, and the profit of generic drugs has declined, and the importance of most pharmaceutical companies has been lowered.
In order to seek better development, executives take the initiative to transform; on the other hand, when the group spins off the lower-profit generic drug business, there will naturally be personnel turnover
.
According to incomplete statistics from public data, in the first half of 2020 alone, more than 160 senior executives in the pharmaceutical industry have left their posts
.
The industry predicts that with the reform of the domestic pharmaceutical industry, as well as the continuous advancement of medical reform policies such as mass procurement and medical insurance negotiations, the changes in the senior management of pharmaceutical companies will continue
.
It is worth noting that from the current job-hopping salary increase rate and turnover rate, the pharmaceutical industry still has a strong demand for professional talents, and is also willing to attract job seekers with higher salary increases than other industries
.
Therefore, this may usher in more development opportunities for medical workers with strength and professional abilities
.
As of October 22 alone, there have been 25 pharmaceutical company executive positions that have changed, involving 23 pharmaceutical companies
.
Among them, there are 18 pharmaceutical companies with senior executives resigning
.
It is reported that these executives involve positions such as chairman, president, and general manager
.
The reasons for resignation mainly include personal reasons and job changes
.
For example, the Human Resources Department of BeiGene announced to employees that the national head of blood tumor sales, Shi Hao, will leave the company on November 15, 2021, to seek external development opportunities
.
The successor has not yet been determined.
Liu Yan, the head of marketing of BeiGene Greater China, will be in charge of the blood tumor sales team.
The handover has already begun.
From the 16th of next month, the blood team of BeiGene will report directly to Liu Flame
.
It is understood that more than one executive from BeiGene has left this year
.
On October 1st, Wu Qingyi, its senior vice president and chief commercial officer of Greater China, also left the company to seek external development opportunities
.
On the same day, Novartis Oncology AMACO Regional Marketing Director Pu Cunxia announced to employees that Novartis Oncology (China) General Manager Alexandre Gibim will be transferred to Novartis's AAA platform as the head of North America, effective from January 1, 2022
.
According to public information, Alexandre Gibim was transferred to Novartis Oncology (China) General Manager on March 1, 2019, and previously served as Novartis (Brazil) President
.
At the same time, from November 1st, IsabelAfonso will take over as the general manager of Novartis Oncology (China), report to Pu Cunxia, the regional market leader of Novartis Oncology AMACO, and join the Novartis Oncology AMACO leadership team
.
It is reported that Isabel Afonso was a 16-year veteran of Novartis and held business and functional leadership positions in Novartis Pharmaceuticals, Animal Health, Consumer Health and Sandoz
.
In addition, SINBON Pharmaceutical also announced on October 24 that it had received a written resignation report from the company’s securities affairs representative Mr.
Lin Hanlin on the 22nd.
.
Due to job adjustments, Mr.
Lin Hanlin applied to resign from the post of securities affairs representative
.
In fact, the frequent resignations or job transfers of senior executives in the pharmaceutical industry have long been the norm in the industry
.
The analysis believes that the industry-driven senior management changes in pharmaceutical companies are mainly due to two reasons.
One is that with the environmental changes in the pharmaceutical industry, innovation has become the development trend of the industry, and the profit of generic drugs has declined, and the importance of most pharmaceutical companies has been lowered.
In order to seek better development, executives take the initiative to transform; on the other hand, when the group spins off the lower-profit generic drug business, there will naturally be personnel turnover
.
According to incomplete statistics from public data, in the first half of 2020 alone, more than 160 senior executives in the pharmaceutical industry have left their posts
.
The industry predicts that with the reform of the domestic pharmaceutical industry, as well as the continuous advancement of medical reform policies such as mass procurement and medical insurance negotiations, the changes in the senior management of pharmaceutical companies will continue
.
It is worth noting that from the current job-hopping salary increase rate and turnover rate, the pharmaceutical industry still has a strong demand for professional talents, and is also willing to attract job seekers with higher salary increases than other industries
.
Therefore, this may usher in more development opportunities for medical workers with strength and professional abilities
.
